Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1273.529 versus mRNA-1273 booster trial in previously vaccinated people
ISRCTN99890480Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing mRNA-1273.529 booster with mRNA-1273 booster active control (2 arms). Primary endpoints: Geometric mean titer against Omicron and prototype strains at Day 29, GMT ratio against Omicron at Day 29 and 4 more. Started Feb 2022; status: completed.
02
Drugs
elasomeranmRNA-1273.529
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN99890480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99890480.